Literature DB >> 23828866

Pediatric onset multiple sclerosis: McDonald criteria 2010 and the contribution of spinal cord MRI.

Hannah-Maria Hummel1, Wolfgang Brück, Steffi Dreha-Kulaczewski, Jutta Gärtner, Jens Wuerfel.   

Abstract

BACKGROUND: Diagnostic magnetic resonance imaging (MRI) criteria have not been sufficiently validated in pediatric multiple sclerosis (MS) despite differences in epidemiologic data and clinical disease courses between pediatric and adult MS.
OBJECTIVE: The objective of this paper is to evaluate the diagnostic applicability and validity of the revised McDonald diagnostic criteria 2010 in a large cohort of pediatric-onset MS patients (POMS) and compare them to previously recommended MRI-based classifications. Furthermore, we aimed to investigate the contribution of spinal cord lesions to the revised McDonald criteria 2010.
METHODS: A cohort of 85 patients with definite MS, age at onset 2.8-18 years, was analyzed in a retrospective multicenter study. Number and regional distribution of T2w and contrast-enhancing T1w lesions at initial and follow-up MRIs were main outcome measures.
RESULTS: In 62% of POMS the initial MRI within four weeks after symptom onset was sufficient to diagnose MS according to the revised McDonald criteria 2010. In a subcohort of patients with spinal MRI at first presentation, 10% reached the dissemination in space (DIS) and dissemination in time (DIT) criteria only by the inclusion of contrast-enhancing spinal lesions.
CONCLUSIONS: The revised McDonald criteria 2010 facilitate the diagnosis of POMS already at first presentation. The addition of a spinal cord MRI was helpful only in selected cases.

Entities:  

Keywords:  McDonald criteria; Multiple sclerosis; magnetic resonance imaging; pediatric onset; spinal cord

Mesh:

Year:  2013        PMID: 23828866     DOI: 10.1177/1352458513493033

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  7 in total

Review 1.  Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.

Authors:  Amy Waldman; Angelo Ghezzi; Amit Bar-Or; Yann Mikaeloff; Marc Tardieu; Brenda Banwell
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

Review 2.  [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Authors:  O Aktas; M P Wattjes; M Stangel; H-P Hartung
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

3.  MRI-based diagnostic biomarkers for early onset pediatric multiple sclerosis.

Authors:  Martin Weygandt; Hannah-Maria Hummel; Katharina Schregel; Kerstin Ritter; Carsten Allefeld; Esther Dommes; Peter Huppke; John Dylan Haynes; Jens Wuerfel; Jutta Gärtner
Journal:  Neuroimage Clin       Date:  2014-07-11       Impact factor: 4.881

Review 4.  MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.

Authors:  Massimo Filippi; Maria A Rocca; Olga Ciccarelli; Nicola De Stefano; Nikos Evangelou; Ludwig Kappos; Alex Rovira; Jaume Sastre-Garriga; Mar Tintorè; Jette L Frederiksen; Claudio Gasperini; Jacqueline Palace; Daniel S Reich; Brenda Banwell; Xavier Montalban; Frederik Barkhof
Journal:  Lancet Neurol       Date:  2016-01-26       Impact factor: 44.182

5.  Reduced peripheral blood regulatory B cell levels are not associated with the Expanded Disability Status Scale score in multiple sclerosis.

Authors:  Shujun Guo; Qingqing Chen; Xiaoli Liang; Mimi Mu; Jing He; Qiang Fang; Chuanwang Song; Daoqian Sang
Journal:  J Int Med Res       Date:  2018-07-19       Impact factor: 1.671

6.  Real-world validation of the 2017 McDonald criteria for pediatric MS.

Authors:  Yu Yi M Wong; C Louk de Mol; Roos M van der Vuurst de Vries; E Daniëlle van Pelt; Immy A Ketelslegers; Coriene E Catsman-Berrevoets; Rinze F Neuteboom; Rogier Q Hintzen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-12-14

Review 7.  Current Advances in Pediatric Onset Multiple Sclerosis.

Authors:  Kristen S Fisher; Fernando X Cuascut; Victor M Rivera; George J Hutton
Journal:  Biomedicines       Date:  2020-03-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.